Jafron Biomedical Co.,Ltd. (SHE:300529)

Market Cap	18.38B
Revenue (ttm)	2.32B
Net Income (ttm)	657.41M
Shares Out	774.36M
EPS (ttm)	0.85
PE Ratio	27.90
Forward PE	20.51
Dividend	0.80 (3.37%)
Ex-Dividend Date	May 26, 2025

Volume	8,905,181
Average Volume	11,497,364
Open	23.11
Previous Close	23.47
Day's Range	23.11 - 23.72
52-Week Range	20.73 - 39.24
Beta	0.43
RSI	54.04
Earnings Date	Aug 29, 2025

About Jafron Biomedical

Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sales of blood purification products for hemadsorption field in worldwide. The company provides solutions for ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, kidney, and liver diseases. It offers HA series hemoperfusion cartridge, BS series bilirubin adsorption column and DNA immunoadsorption column, hemoperfusion machine, and blood purification machine; and other products, such as hemodialyzer, disinfectants, hemodialysis co...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1989
• Employees: 2,797
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300529

Financial Performance

In 2024, Jafron Biomedical's revenue was 2.68 billion, an increase of 39.27% compared to the previous year's 1.92 billion. Earnings were 820.20 million, an increase of 87.91%.